SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)- pyridin-3-ylmethyl]-piperazine monohydrochloride): A novel dopamine D 2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug

Andrew C. McCreary*, Jeffrey C. Glennon, Charles R. Ashby, Herbert Y. Meltzer, Zhu Li, Jan Hendrik Reinders, Mayke B. Hesselink, Stephen K. Long, Arnoud H. Herremans, Herman Van Stuivenberg, Rolf W. Feenstra, Chris G. Kruse

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Fingerprint Dive into the research topics of 'SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)- pyridin-3-ylmethyl]-piperazine monohydrochloride): A novel dopamine D <sub>2</sub> receptor antagonist and 5-HT<sub>1A</sub> receptor agonist potential antipsychotic drug'. Together they form a unique fingerprint.

Medicine & Life Sciences